March 18, 2020 / 9:12 PM / 11 days ago

BRIEF-Pfizer Announces Positive Top-Line Results From Third Phase 3 Trial Of Abrocitinib

March 18 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THIRD PHASE 3 TRIAL OF ABROCITINIB FOR MODERATE TO SEVERE ATOPIC DERMATITIS, WHICH SHOWED IMPROVEMENTS IN SKIN CLEARANCE, DISEASE EXTENT AND SEVERITY, AND ITCH

* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THIRD PHASE 3 TRIAL OF ABROCITINIB FOR MODERATE TO SEVERE ATOPIC DERMATITIS, WHICH SHOWED IMPROVEMENTS IN SKIN CLEARANCE, DISEASE EXTENT AND SEVERITY, AND ITCH

* PFIZER INC - JADE COMPARE TRIAL MET ALL CO-PRIMARY ENDPOINTS

* PFIZER INC - STUDY INCLUDED DUPILUMAB IN ACTIVE CONTROL ARM

* PFIZER INC - SAFETY PROFILE FOR ABROCITINIB CONSISTENT WITH PREVIOUS STUDIES

* PFIZER INC - DUPILUMAB, ACTIVE CONTROL ON THESE PRIMARY ENDPOINTS, DEMONSTRATED SUPERIORITY TO PLACEBO AT WEEK 12 AND WEEK 16

* PFIZER INC - PERCENTAGE OF PATIENTS WHO HAD SIGNIFICANT REDUCTION IN ITCH BY WEEK 2 OF TREATMENT WAS STATISTICALLY SUPERIOR FOR 200MG ABROCITINIB DOSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below